Stephen L. Malaska

"We are excited about the potential for this novel molecule," said Stephen Malaska, General Counsel and Vice President of Business Development of CEPTYR.
...
Stephen L. Malaska, 425-806-1527 425-806-1550 smalaska@ceptyr.com

Email Article Print Article

"We are excited about the potential for this novel molecule," said Stephen Malaska, General Counsel and Vice President of Business Development of CEPTYR.

"We are excited about the potential for this novel molecule," said Stephen Malaska, General Counsel and Vice President of Business Development of CEPTYR.
...
Stephen L. Malaska, 425-806-1527 425-806-1550 smalaska@ceptyr.com

"We are excited about the potential for this novel molecule," said Stephen Malaska, General Counsel and Vice President of Business Development of CEPTYR.
...
Stephen L. Malaska General Counsel, VP Business DevelopmentCEPTYR, Inc.3830 Monte Villa Parkway, Suite 200Bothell, WA 98021Phone: 425.806-1527Fax: 425.806-1599

DEP-1, a member of the protein tyrosine phosphatase (PTP) enzyme family, has been implicated in vascular development and other functions, and thus may be an important target for therapy of several human diseases, particularly cancer, said Stephen L. Malaska, General Counsel and Vice President of Business Development of CEPTYR.

"DEP-1, a member of the protein tyrosine phosphatase (PTP) enzyme family, has been implicated in vascular development and other functions, and thus may be an important target for therapy of several human diseases, particularly cancer," said Stephen L. Malaska, General Counsel and Vice President of Business Development at CEPTYR.